Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Hold the phone, biopharma: FDA-imposed clinical holds are on the rise

4 years ago

In latest setback for solid tumor CAR-T, Celyad pauses trial following two patient deaths

4 years ago

Merck drops out of a $125M KRAS alliance with Moderna, taking a step away from the Covid-19 star

4 years ago

Building on CRISPR success, Intellia inks deal for new manufacturing facility in Waltham, MA

4 years ago

With Spark safely tucked into Roche, its founding CEO is off to search for new adventures

4 years ago

Takeda signs off on a $2B deal aimed at bypassing AAV roadblocks on the way to gene therapy 2.0

4 years ago

Lilly breaks the bank on the potential for RNA with $700M investment in Boston's Seaport

4 years ago

Homology joins BioMarin in halting gene therapy studies for rare metabolic disease

4 years ago

FDA starts probe into a clinical trial death as next-gen CAR-T researchers stop enrollment

4 years ago

BioMarin gene therapy could be on hold 'for several quarters' after FDA mandates new preclinical tests

4 years ago

Some genes are too large to fit into AAV vectors. UCB, Novartis back $57M idea to deliver them in parts instead

4 years ago

Biotech bear market be damned, CAR-T player Arcellx raises $123M IPO

4 years ago

Searching for CRISPR 2.0, Intellia spends $45M cash on an unknown Berkeley spinout

4 years ago

FDA slams clinical hold on LogicBio's gene editing drug after clotting cases in child patients

4 years ago

Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact

4 years ago

Oxford Biomedica enters the AAV manufacturing world, buying Homology's in-house business

4 years ago

Can new manufacturing approaches finally make a decades-old cell therapy idea a reality?

4 years ago

Well-connected, Gilead-backed biotech gets another stack of cash to pursue CAR-Ts for autoimmune disease

4 years ago

FDA slams door to pivotal trial for bubble boy disease gene therapy as Mustang Bio runs into another hold

4 years ago

'Altos was really a once-in-a-lifetime opportunity': Hal Barron reflects on his big move

4 years ago

What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain

4 years ago

UK upstart raises $100M in bid to digitize and standardize cell and gene therapy manufacturing

4 years ago

FDA orders DMD trial halt, raising questions about a whole class of promising drugs

4 years ago

Three years, a clinical hold and a death later, Sarepta abandons partnered pivotal-stage gene therapy

4 years ago

First page Previous page 31 32 333435 36 37 Next page Last page